Contrasting CohBar (NASDAQ:CWBR) and Immunome (NASDAQ:IMNM)

CohBar (NASDAQ:CWBR) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Profitability

This table compares CohBar and Immunome’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CohBar	N/A	N/A	N/A
Immunome	-3,014.59%	-48.63%	-41.62%

Earnings and Valuation

This table compares CohBar and Immunome”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CohBar	N/A	N/A	-$12.18 million	N/A	N/A
Immunome	$14.02 million	43.72	-$106.81 million	($8.11)	-1.21

CohBar has higher earnings, but lower revenue than Immunome.

Institutional and Insider Ownership

2.5% of CohBar shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 6.5% of CohBar shares are owned by insiders. Comparatively, 8.6% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for CohBar and Immunome, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CohBar	0	0	0	0	0.00
Immunome	0	0	7	0	3.00

Immunome has a consensus target price of $28.83, indicating a potential upside of 193.62%. Given Immunome’s stronger consensus rating and higher possible upside, analysts plainly believe Immunome is more favorable than CohBar.

Volatility and Risk

CohBar has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Immunome has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.

Summary

Immunome beats CohBar on 7 of the 11 factors compared between the two stocks.

About CohBar

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

About Immunome

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.